PURCHASE - Cognition Therapeutics, Inc., , a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024.
NEW YORK, April 01, 2024 Cognition Therapeutics, Inc. , a clinical stage company developing drugs that treat neurodegenerative disorders, today announced it will host a virtual KOL event on.
PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D.,
Cognition Therapeutics (CGTX) Reports Positive Topline Results for CT1812 Phase 2 SEQUEL Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.